KDR and hepatocellular carcinoma: Unlike systemic drugs therapies for HCC clinically available, such as multi-kinase inhibitors (Sorafenib, lenvatinib, cabozantinib, regorafenib), antagonistic anti-VEGFR2 monoclonal antibody (ramucirumab), immune checkpoint inhibitors (nivolumab and pembrolizumab) and combined alternatives which induce hepatocytes apoptosis45, or pre-clinically in vivo or in vitro tested compounds that decrease the mitochondrial function in HCC such as biguanide drugs (metformin and phenformin)46, sulfonamides FH535 and Y347 and sorafenib with nitazoxanide or nidosamide48.